PORPHYSOMES

Phase 1Small molecule

UUniversity Health Network, Toronto

PORPHYSOMES is one of 5 small molecule programs targeting Gynaecological Cancers. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gynaecological CancersRecruiting

Gynaecological CancersPhase 1

Recruiting

Competition

Competitive Landscape

4 competitors in Gynaecological Cancers

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 2

1 2

Lynparza

AstraZeneca

Phase 2

1 3

Ceralasertib

AstraZeneca

Phase 2

1 4

IMGN151

AbbVie

Phase 1

1 5

PORPHYSOMES

UUniversity Health Network, Toronto

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Gynaecological Cancers

NCT06977126

Clinical

Trials by Indication[1]

Gynaecological Cancers1 trial

Study to Assess the Safety and Effects of Porphysome Nanoparticles for Imaging in Gynaecological Cancers

Recruiting·UUniversity Health Network, Toronto·Phase 1·NCT06977126·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PORPHYSOMES. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PORPHYSOMES compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PORPHYSOMES. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Health Network, Toronto company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity Health Network, Toronto

PORPHYSOMES

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Gynaecological Cancers1 trial

References

Drug Info

Quick Facts

Related News